Abstract Leishmaniasis is a major public health problem and till date there are no effective vaccines available. The control strategy relies solely on chemotherapy of the infected people. However, the present repertoire of drugs is limited and increasing resistance towards them has posed a major concern. The first step in drug discovery is to identify a suitable drug target. The genome sequences of Leishmania major and Leishmania infantum has revealed immense amount of information and has given the opportunity to identify novel drug targets that are unique to these parasites. Utilization of this information in order to come up with a candidate drug molecule requires combining all the technology and using a multi-disciplinary approach, right from characterizing the target protein to high throughput screening of compounds. Leishmania belonging to the order kinetoplastidae emerges from the ancient eukaryotic lineages. They are quite diverse from their mammalian hosts and there are several cellular processes that we are getting to know of, which exist distinctly in these parasites. In this review, we discuss some of the metabolic pathways that are essential and could be used as potential drug targets in Leishmania.
Introduction
Leishmaniasis is a group of parasitic diseases caused by at least 20 different species of the protozoan parasite Leishmania. It constitutes of a wide spectrum of diseases ranging in severity from simple cutaneous lesions to the usually fatal visceral form. The parasite is transmitted through the bite of sandfly to the mammalian hosts. The disease is endemic in 88 countries and affects as many as 12 million people around the globe with an incidence of 0.5 million cases of the visceral form of the disease and 1.5-2.0 million cases of the cutaneous form of the disease, causing extensive mortality and morbidity.
Since, effective vaccines against leishmaniasis are still under development, the current control measures rely solely on chemotherapy. Pentavalent antimonials are the standard first line of treatment but emergence of resistance towards them, has limited their usefulness. Alternative chemotherapeutic treatments with amphotericin B and its lipid formulation, miltefosine and paromomycin are available but their use is limited either due to toxicity or high cost of treatment. The current challenges in the chemotherapy include availability of very few drugs, emergence of resistance to the existing drugs, their toxicity and lack of cost-effectiveness. Therefore, it is of utmost importance to look for effective drugs and new drug targets for the treatment of leishmaniasis.
There seems to be a welcome change in terms of flow of funds for antiparasitic drug discovery. Some of the organisations like Institute of One World Health (IOWH), Drugs for Neglected Diseases Initiative (DNDi), Bill and Melinda Gates foundation have had a significant impact on working towards the drug development for tropical diseases. This has enabled technological advances in the field, which includes publicly funded sequencing of the genomes, thus fastening up the course towards drug development. A major breakthrough in the field is the availability of the complete genome sequence of various species of Leishmania like, L. major (Ivens et al. 2005) , L. infantum and L. braziliensis. It has provided us with enormous information about the parasite genome for our better understanding of these organisms. With the availability and easily accessible genome sequences, the conventional method of drug target identification, which was done on the basis of the biochemical and physiological differences between the pathogen and host, is now changing. Microarrays and proteome analysis make use of the genome sequences and has allowed us to find genes unique to the parasite, some species-specific genes that can help us understand the pathogen better. Several bioinformatic approaches have also been proposed which will fasten the pace to come up with anti-leishmanial drugs (Myler 2008) . The analysis of the complete genome sequence may significantly contribute in drug development by revealing the presence of novel enzymes and receptors. Furthermore, the comparison of the parasite genome with the human genome sequence will make the identification of genes, unique to the parasite, easier.
Identification of drug targets
One of the characteristic features in the process of drug development is target identification in a biological pathway. In theory, during identification of a target in a pathogen, it is important that the putative target should be either absent in the host or substantially different from the host homolog so that it can be exploited as a drug target. Trypanosomatids, phylogenetically, branch out quite early from the higher eukaryotes. In fact, their cell organization is significantly different from the mammalian cells and thus, it is possible to find targets that are unique to these pathogens. Secondly, the target selected should be absolutely necessary for the survival of the pathogen. It is also important to consider the stage of the life-cycle of the pathogen in which the target gene is expressed. It is crucial to look at the biochemical properties of the protein; it should have a small molecule binding pocket, so that specific inhibitors can be designed and if the target protein is an enzyme, its inhibition should lead to loss in cell viability. It is of high importance that the target selected should be assayable. Inexpensive and specific assay system should be available for high-throughput screening of molecules (Pink et al. 2005; Barrett et al. 1999) .
Potential drug targets in Leishmania
Sterol biosynthetic pathway Sterols are important components of the cell membrane that are vital to cellular function and maintenance of cell structure. Unlike mammalian cells, which have cholesterol as the major membrane sterol, trypanosomatids synthesize ergosterol and other 24-methyl sterols that are required for their growth and viability. These sterols are absent from the mammalian cells. Therefore, the sterol biosynthetic pathway from Leishmania is considered to be an important drug target (Fig. 1) .
One of the enzymes that is being studied deeply is squalene synthase (SQS) (EC 2.5.1.21) that catalyzes the first committed step of sterol synthesis by coupling two farnesyl molecules to form squalene. Zaragozic acids and quinuclidines are known to inhibit SQS. Two quinuclidine derivatives, ER-119884 and E5700 have been shown to be potent anti-Leishmania (Fernandes Rodrigues et al. 2008) and Trypanosoma ) agents. The inhibition of SQS by these compounds decreased the parasite's endogenous sterol levels which had an antiproliferative effect on the parasite. In L. amazonensis, IC 50 value of ER-119884 and E5700 for promastigotes was found to be 10 and 30 nM respectively (Fernandes Rodrigues et al. 2008) . Squalene is converted to 2,3-oxidosqualene by the enzyme squalene epoxidase (EC 1.14.99.7). It converts squalene chain to tetracyclic sterol skeleton. Terbinafine, an allylamine, is known to inhibit squalene epoxidase. It has been shown that terbinafine inhibits the growth of promastigotes and intracellular amastigotes and leads to changes in structural organization in mitochondrion ( Vannier-Santos et al. 1995) . When it is used in combination with ketoconazole, another inhibitor of ergosterol biosynthesis, the effect is synergistic. Another class of inhibitors, bisphosphonates, inhibits the isoprenoid pathway that is catalyzed by the enzyme farnesyl diphosphate synthase (FPPS). They have been tested in vivo and in vitro against the protozoan parasites (Martin et al. 2001; Docampo and Moreno 2008) . A potent inhibition of the cell growth and suppression of the activity of isolated enzymes (from L. major) was observed thus validating the isoprenoid pathway as a drug target. Another important putative target in ergosterol biosynthesis is the enzyme D 24,25 -sterol methyltransferase (SMT) (EC 2.1.1.41). This enzyme is only present in trypanosomatids and absent from the human host. Therefore, this enzyme could be exploited as a potential drug target. Azasterols are known to inhibit SMT in case of Candida spp. (Ishida et al. 2009 ). The effect of azasterols has been studied on Leishmania and Trypanosoma species among the protozoan parasites. Several azasterols have been shown to have anti-proliferative effect with their IC 50 s in submicromolar to nanomolar range against L. amazonensis (Magaraci et al. 2003; Lorente et al. 2004) , signifying that this step could be a potential chemotherapeutic target. In, L. amazonensis, they also led to disorganization of the mitochondrial membrane followed by intense swelling and loss of matrix contents (Vivas et al. 1996; Rodrigues et al. 2002) . Interestingly, azasterols when used in combination with azoles act synergistically and are even more effective suggesting that inhibiting multiple steps of this pathway, that is, combination therapy may be used against the parasitic protozoa.
Glycolytic pathway
The energy metabolism of trypanosomatids solely depends on the carbon sources available in the host. Since the African trypanosomes lack a functional Krebs cycle, they use glycolysis as the only source of ATP generation (Opperdoes 1987) . Seven of the glycolytic enzymes are compartmentalized in peroxisome-like organelles, glycosomes, which is a unique feature of trypanosomatids (Fig. 2) . The unique compartmentalization of glycolytic enzymes in glycosomes in Leishmania and their large phylogenetic distance with the mammalian hosts provides them with unique features. These features can be exploited by designing specific inhibitors on the basis of the structure of the parasitic enzymes. Structure based drug designing is being employed to obtain compounds that bind to the enzymes with high affinity. The 3-D structures are available for some of the trypanosomatid enzymes: glyceraldehydes-3-phosphate dehydrogenase (EC 1.2.7.6) (Vellieux et al. 1993; Kim et al. 1995) , triosephosphate isomerase (5.3.1.1) (Wierenga et al. 1991; Williams et al. 1999) , phosphoglycerate kinase (EC 2.7.2.10) (Bernstein et al. 1997) , pyruvate kinase (2.7.1.40) (Rigden et al. 1999) , fructose-1,6-bisphosphate aldolase (EC 4.1.2.13) (Chudzik et al. 2000) and glycerol-3-phosphate dehydrogenase (EC 1.1.1.8) (Suresh et al. 2000) . The differences in the 3-D structures of the parasite and host enzymes can be used to design specific inhibitors (Verlinde and Hol 1994) .
Specific inhibitors have been designed for the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) based on its crystal structure. Adenosine analogs were synthesized as tight binding inhibitors that occupy the pocket on the enzyme that accommodates adenosyl moiety of NAD (4) aldolase (5) triosephosphate isomerase (6) glyceraldehyde-3-phosphate dehydrogenase (7) phosphoglycerate kinase (8) glycerol-3-phosphate dehydrogenase (9) glycerol kinase (10) phosphoglycerate mutase (11) enolase (12) pyruvate kinase J Parasit Dis co-substrate. Adenosine was shown to be a poor inhibitor of the enzyme but its analog, with substitutions at the 2 0 position of ribose and N 6 -position of adenosine (disubstituted analogs) resulted in enhanced inhibition of the enzyme. One of the analogs, N 6 -(1-naphthalenemethyl)-2 0 -(3-methoxybenzamido) adenosine inhibited growth of L. mexicana with IC 50 of 0.28 lM (Aronov et al. 1999 ). This indicates that it is possible to block the energy production by synthesis of specific inhibitors of glycolytic pathway enzymes. Since glycolysis is the only source of energy for these parasites, it could serve as an excellent drug target.
Purine salvage pathway
The parasitic protozoa, including Leishmania lack the enzymes to synthesize purine nucleotides de novo, therefore, they have to depend upon the purine salvage system to utilize purine bases from their mammalian hosts (Fig. 3) . Purine bases are translocated through the parasite cell surface by nucleoside transporters.
Nucleoside transporters
They are involved in transport of nucleosides across the membrane. Two specific transporters which have been well documented from Leishmania are LdNT1 (present in both promastigote and amastigotes) and LdNT2 (present in amastigotes) (Vasudevan et al. 1998; Carter et al. 2000) . LdNT1 is responsible for transportation of adenosine and pyrimidine nucleosides and LdNT2 transports purine nucleosides (inosine and guanosine). LdNT1 and LdNT2 were first cloned from L. donovani by functional complementation of adenosine-pyrimidine transport deficient mutant, TUBA5 (tubercidin resistant) and inosine-purine transport deficient mutant FBD5 (Formycin resistant), respectively. Two very closely related genes encoding for pyrimidine nucleoside transporters LdNT1.1 and LdNT1.2 have been identified which show very high affinity towards pyrimidines. It has been seen that point mutations in LdNT1.1 and LdNT2 alter the substrate specificity and confer resistance towards drug (Vasudevan et al. 2001; Galazka et al. 2006) . Two purine nucleobase transporters have also been identified from L. major, LmaNT3 and LmaNT4. LmaNT3 transports only bases hypoxanthine, xanthine, adenosine and guanine but not nucleosides whereas, LmaNT4 takes up only adenine at neutral pH but at acidic pH, it can take up hypoxanthine, guanine and xanthine as well (Ortiz et al. 2009 ). Its function is required for the optimal viability of the parasite inside the acidic phagolysosome of human macrophages. The parasitic transporters are different from the mammalian transporters in terms of their higher specificity towards the substrate. The fact that there are so many pathways for the uptake of purines; it is very difficult to target them with selective inhibitors. But, they will remain pharmacologically important as these transporters also uptake toxic nucleoside analogs which are inhibitory to the cell growth.
Purine Salvage enzymes
In Leishmania, the enzyme phosphoribosyltransferase (PRT), that converts dephosphorylated purines to nucleosides monophosphates, plays an important role in salvage of purines. Three PRTs have been identified and characterized from Leishmania (Glew et al. 1988 ) namely, adenine phosphoribosyl transferase (APRT) (EC 2.4.2.7), hypoxanthine-guanine phosphoribosyl transferase (HGPRT) (EC 2.4.2.8) and xanthine phosphoribosyl transferase (XPRT) (2.4.2.22). HGPRT converts hypoxanthine to inosine monophosphate and guanine to guanine monophosphate. Various inhibitors have been designed to target HGPRT due to its difference in substrate specificity with the host enzyme. The most common inhibitor used is allopurinol that is phosphorylated by HGPRT and incorporated into nucleic acid thus leading to selective death of the parasite (Marr 1983; Fish et al. 1985) . Allopurinol has been shown to be effective against cutaneous (Martinez and Marr 1992) and visceral Leishmaniasis (Kager et al. 1981) . Allopurinol when used with other anti-leishmanial drugs was found to be even more effective. Phthalic anhydride derivative (structural analogs of purine bases), TF1 and phthalimide derivative, TF2, have also been shown to be effective against Leishmania (Somoza et al. 1998 ). However, it has been found that PRTs are not essential for parasite's survival. This is possible since there are various alternative purine salvage pathways present in Leishmania. Therefore, it is necessary to (2) adenine deaminase (3) guanine deaminase (4) adenosine deaminase (5) nucleoside kinase (6) nucleotidase (7) AMP deaminase (8) AMP kinase (9) GMP kinase (10) IMP dehydrogenase (11) GMP synthetase (12) GMP reductase. AMP adenosine monophosphate; ADP adenosine diphosphate; IMP inosine monophosphate; XMP xanthine monophosphate; GMP guanosine monophosphate; GDP guanosine diphosphate target more than one enzyme at a time to come up with an anti-leishmanial chemotherapy.
GPI biosynthetic pathway as drug target
Glycosylphosphatidylinositol (GPI) glycolipids are major cell surface constituents in the Leishmania parasites that act as anchor to various cell surface glycoproteins. The cell surface of the promastigotes is coated by glycocalyx which consists of GPI anchored glycoproteins, GPI-anchored lipophosphoglycan (LPG) and a family of free GPIs, called as glycoinositolphospholipids (GIPLs), in high densities (Fig. 4) . They protect the parasite from the alternate complement pathway and external hydrolases. LPG is essential for the infectivity of L. major promastigotes in both the mammalian and insect hosts Sacks et al. 2000) . The core glycan unit of all protein linked GPIs is conserved and has the structure (Ethanolamine-P-Mana1-2Mana1-6Mana1-4GlcNH 2 ), which is linked to the 6-position of D-myo-inositol ring of phosphatidylinositol (PI) . GPI anchors are synthesized in a step-wise manner in endoplasmic reticulum membrane and then attached to the nascent proteins. These GPI anchored proteins are then transferred to the plasma membrane via the secretory pathway. GPI biosynthesis is essential for bloodstream form T. brucei parasites and has been validated as a chemotherapeutic target (Ferguson 2000) . The first step in GPI biosynthesis is the formation of GlcNAc-PI, by the transfer of N-acetylglucosamine (GlcNAc) from UDP-GlcNAc to PI. The reaction is catalyzed by the protein complex, GPI-N-acetylglucosaminyltransferase (GPI-GnT). Then, GlcNAc-PI is de-N-acetylated to form GlcN-PI, catalyzed by GlcNAc-PI-de-N-acetylase. This is an essential step for all GPI biosynthetic pathways. Trypanosomal enzyme has been shown to be zinc metalloenzyme (Urbaniak et al. 2005 ). The enzymes from T. brucei ) and L. major showed narrow substrate specificity than the human homolog in vitro. Substrate specificity was determined using substrate analogs of GlcNAc-PI. The substrate analog GlcNR-PI where R is an acyl group larger than propionyl group were not de-N-acetylated by the enzyme but when this group was substituted with benzoyl group, the analog was shown to inhibit the parasitic enzyme and not the human counterpart. The difference in the substrate specificities of the two enzymes has been exploited and two synthetic GlcNAc-PI analogs, GlcNCONH 2 -b-PI and GlcNCONH 2 -(2-O-octyl)-PI were shown to be T. brucei specific suicide inhibitors (Smith et al. 2001) .
Differences between the parasitic and mammalian GPI biosynthetic pathways occur from GlcN-PI onwards, including the timing of inositol acylation and deacylation. The next step in GPI biosynthesis in case of parasites is mannosylation of GlcN-PI which is followed by inositol acylation, whereas, in yeast and human, inositol acylation is a pre-requisite for mannosylation. The trimannosyl core of GPI anchors is added stepwise and involves three distinct mannosyl transferases (MT). Mannosyltransferase III (MTIII) has been found to be substrate specific. There is a difference in the structure of the substrates for the mammalian and the trypanosomal MTIII which suggests that species-specific inhibition can be achieved by synthesizing small molecule inhibitors (Urbaniak et al. 2008) . The mannose donor for all GPI-mannosyl transferases is dolichol-P-mannose (Dol-P-Man). Dol-P-Man is synthesized by the enzyme Dol-P-Man synthase which can be inhibited by the addition of lipopeptide antibiotic amphomycin which forms a complex with Dol-P, and thereby inhibiting GPI biosynthesis. The enzymes MT require divalent cations for their function and can be inhibited in vitro by metal chelators like EDTA. GlcN-PI analog, GlcN-(2-O-hexadecyl)PI inhibits specifically the first mannosyltransferase in T. brucei in a competitive manner.
The next step is the acylation of inositol. In T. brucei, it can be inhibited in vivo as well as in vitro using a serine esterase inhibitor phenylmethylsulphonyl fluoride (PMSF) leading to accumulation of the Man 3 -GlcN-PI intermediate in T. brucei. This inhibition of trypanosomal inositol acylation was also observed in vitro with either GlcN-(2-O-methyl)-PI or GlcN-(2-O-octyl)-PI . The final step of synthesis of GPI core glycan structure, involves transfer of ethanolamine phosphate to Fig. 4 Structure of the major GPI classes synthesized by L. mexicana promastigotes. These glycolipids act as anchors for major cell surface proteins (GPI anchored proteins), surface lipophosphoglycans (LPGs) and free glycolipids (GIPLs). M2-4 denotes GPIs with the structures Man 2-4 GlcN-PI; EP denotes the presence of an EtN-P cap or side chain; and the prefix i denotes the presence of an a1-3-linked mannose in the core structure 6th position of the third mannose. Since, PMSF inhibits the inositol acylation of the intermediate Man 3 -GlcN-PI to form Man 3 -GlcN-(acyl)-PI in T. brucei, the addition of ethanolamine phosphate is prevented (Guther et al. 1994) . The mammalian enzyme is not inhibited by PMSF. This selective inhibition implies significant differences in the structure of the enzymes which can be exploited for designing specific inhibitors. After the completion of GPI anchor synthesis, lipid remodeling takes place which involves exchange of fatty acid components with other fatty acid of the lipid moiety or the whole lipid component. T. brucei contains myristate as the major lipid component in its GPI-anchored variable surface glycoproteins. The major product of fatty acid biosynthesis in T. brucei is myristate which is required to be incorporated into GPI anchors and therefore, this pathway can be targeted in T. brucei. Thiolactomycin, an inhibitor of fatty acid synthesis leads to death of parasites. Myristate specific remodeling has been reported for Leishmania GPIs also. Incorporation of myristate analogs into the GPI anchor is toxic to trypanosomes. Therefore, the enzymes of fatty acid remodeling are possible targets for anti-trypanosome chemotherapy. The mature GPI precursor is transferred to the protein by transamidation reaction by a multimeric protein complex, where, COOH terminal signal peptide is replaced by the formation of amide linkage to amino group of ethanolamine phosphate linked to the third mannose of GPI anchor. The protein components differ in different species, suggesting that these differences between the parasite and mammalian enzymes can be exploited for drug designing.
Protein kinases as drug targets
Cyclin dependent kinases (CDKs) are known to play a crucial role in cell division. They have been found to be abnormally regulated in cancer cells and have therefore drawn attention as drug targets. In Leishmania, the cdc-2 related kinase (CRK) family has attracted attention as potential drug targets. They are homologs of CDKs and are thought to be essential for cell cycle progression. Two putative CDKs in L. mexicana, LmexCRK1 and LmexCRK3 (Hassan et al. 2001 ) have been found to be essential to the promastigotes form of the parasite. Attempts to generate null mutants of CRK3 resulted in change in ploidy of the parasite (Hassan et al. 2001) . CRK3 is found to be active throughout the life cycle in L. mexicana (Grant et al. 1998) . CRK3 from L. major was able to complement a temperature sensitive cdc-2 mutant in S. pombe. Inhibitors of CRK3, inhibited the growth and replication of L. donovani amastigotes in peritoneal macrophages. These compounds also led to aberrant DNA content and abnormal morphology of the cells as determined by the flow cytometry (Grant et al. 2004 ).
MAP kinases
Mitogen-activated Protein (MAP) kinases are mediators of signal transduction and important regulators of cell differentiation and cell proliferation in eukaryotic cells. So far, ten MAP kinases have been identified in L. mexicana, of which LmxMKK, LmxMPK and LmxMPK9 (Wiese 1998; Wiese et al. 2003; Bengs et al. 2005 ) have been studied intensely. Null mutants of both LmxMKK and LmxMPK9 are viable both in amastigote and promastigote stages of the life cycle and therefore, neither of them can be exploited as drug targets. However, null mutants of LmxMPK, has the ability to infect peritoneal macrophages and differentiate into amastigotes, but are unable to proliferate within the parasitophorous vacuole. This phenotype was reverted back by the reintroduction of LmxMPK to the mutant (Wiese 1998) . Therefore, LmxMPK is found to be essential for the growth of the more relevant amastigote form and can be used as a drug target.
Proteinases as drug targets
Proteinases are of four main types-cysteine, serine, aspartate and metallo-enzymes. The name is given on the basis of the residue present in the active site. In case of parasitic protozoa, the most identified and characterized are the cysteine proteinases (CPs), which are homologous to mammalian cathepsins. CPs have attracted attention as potential drug targets because of their role in host cellparasite interaction, as putative virulence factor, and being structurally different from the mammalian homolog.
Analysis of L. major genome database revealed that there are genes encoding for as many as 65 CPs. CPs are further divided into different types. CPA and CPB are both cathepsin L-like proteinases in terms of amino acid sequence. CPC is cathepsin B-like proteinases. CPA, CPB and CPC are involved in host-parasite interaction as determined by gene replacement studies in L. mexicana. L. mexicana deficient in the multicopy CPB gene array (Dcpb) have reduced virulence with poor lesion growth in BALB/c mice (Alexander et al. 1998) . A natural inhibitor of CP (ICP) from L. mexicana has been characterized and has been shown to be a potent inhibitor of CPB. BALB/c mice infected with mutants overexpressing ICP were able to resolve the infection faster (Bryson et al. 2009 ). In another study, T. brucei infected mice were treated with cysteine proteinase inhibitor, carbobenzoxy-phenylalanyl-alaninediazomethyl ketone (Z-Phe-Ala-CHN 2 ). It led to alteration in cell morphology and was lethal to the cultured parasites (Scory et al. 2007 ). These studies provide evidence of the therapeutic potential of the inhibitor of cysteine proteinases. In T. brucei, RNAi studies have shown a cathepsin B like protease tbcatB, as a key target (Mackey et al. 2004 ).
Parasites containing single copy of tbcatb show enlargement of lysosome and decreased degradation of endocytosed host proteins (O'Brien et al. 2008) . The CPs are also of interest because of their structural differences with the mammalian CPs. The protein tbcatB has been crystallized and its structure confirms an occluding loop which is important for substrate binding (Kerr et al. 2010) . This loop creates a larger prime side pocket in active site cleft than is found in mammalian cathepsin B. The difference in the structure of the proteins may be utilized for design of inhibitors.
Folate biosynthesis
Folate pathway has been of interest as a drug target and has been used in anti-cancer and anti-malarial chemotherapy. Folates are important cofactors used in a variety of metabolic pathways like DNA and RNA synthesis and amino acid metabolism. Since they are essential for growth, the enzymes involved in their synthesis have been of interest as drug targets, particularly, thymidylate synthase (TS) (EC 2.1.1.45) and dihydrofolate reductase (DHFR) (EC 1.5.1.3) which is responsible for converting dihydrofolate to tetrahydrofolate, an important cofactor in the synthesis of thymine. TS and DHFR catalyze sequential reactions to synthesize dTMP (Fig. 5a ). Both the enzymes have been studied intensively and used as targets for chemotherapy. Interestingly, TS and DHFR exist on a single polypeptide in case of trypanosomatids, with DHFR domain on amino terminus and TS domain on carboxy terminus. TS-DHFR has been characterized from L. major. The classic inhibitors of DHFR were found to be ineffective against Leishmania (Neal and Croft 1984) . An answer to that came from the genetic analysis which showed amplification of the gene pteridine reductase (PTR1) (1.5.1.33) in some of the mutants in Leishmania which were resistant to methotrexate (an inhibitor of DHFR-TS) . PTR1 can reduce both pterins and folates (Fig. 5b) and is much less susceptible to inhibition by anti-folates, as revealed by structural studies, targeted against DHFR. Therefore, it can act as a bypass system for DHFR-TS. A number of compounds have been screened against PTR1 in L. major . Several compounds were found to be inhibiting both DHFR-TS and PTR1. However, only four such compounds were identified that inhibited both the enzymes and the growth of the parasite potently. This indicates that an inhibitor is required that targets both the enzymes simultaneously or two compounds that can be used in combination specifically inhibiting both the enzymes.
Glyoxalase system
The Glyoxalase system functions to detoxify the cell by removal of toxic and mutagenic intermediate, methylglyoxal, which is mainly formed as a by-product of glycolysis. It is also formed during threonine catabolism and acetone oxidation (Cooper 1984; Vickers et al. 2004 ). The glyoxalase system comprises of two enzymes viz. glyoxalase I (lactoyl glutathione lyase) (EC 4.4.1.5) and Glyoxalase II (hydroxyacyl glutathione hydroxylase) (EC 3.1.2.6) and uses glutathione as a cofactor. However, trypanosomatids rely on a trypanothione dependent glyoxalase system (Fig. 6 ) which is unique to these parasites, where glyoxalase I catalyzes the formation of S-D-lactoyltrypanothione from hemithioacetal. Hemithioacetal is formed non-enzymatically from methylglyoxal and reduced trypanothione. S-D-lactoyltrypanothione is further hydrolysed to D-lactate regenerating trypanothione by glyoxalase II (Vickers et al. 2004) .
Glyoxalase I has been characterized from L. donovani (Padmanabhan et al. 2005 ) and L. major (Vickers et al. 2004 ). The enzyme is highly substrate specific as it depends entirely on trypanothione as substrate, instead of glutathione as in their mammalian hosts. Superposition of L. donovani glyoxalase I with crystal structure of E. coli glyoxalase I showed that its substrate binding loop is smaller in comparison to glutathione utilizing enzymes and is devoid of positively charged residues, as observed for human and E. coli homolog (Padmanabhan et al. 2005) . L. donovani glyoxalase I has been found to be an essential gene in the parasite (Chauhan and Madhubala 2009) . Glyoxalase II was first identified from T. brucei. It is expressed in both procyclic and bloodstream forms of T. brucei (Irsch and Krauth-Siegel 2004) . Glyoxalase II has Folate synthesis pathway. a The figure shows the synthesis of dTMP by the enzyme TS which uses methylene tetrahydrofolate and converts it into dihydrofolate. It is then converted back to tetrahydrofolate by the enzyme DHFR. b The schematic diagram shows that the enzyme pteridine reductase (PTR1) can reduce both pterins and folates also been characterized from L. donovani (Padmanabhan et al. 2006 ). Sequence comparison shows that it lacks the basic residues in its active site which are conserved in human homolog. These residues are important for binding to glutathione. The substrate for L. donovani Glyoxalase II is thioester of trypanothione, which is positively charged. Therefore, it cannot be accommodated in the active site of the human enzyme. This observation strongly suggests that the parasitic enzymes are highly substrate specific. Therefore, trypanothione-dependent glyoxalase pathway has drawn attention for additional biochemical and genetic investigation as a possible target for rational drug design.
Trypanothione pathway
As discussed above, trypanothione (bis-(glutathionyl) spermidine) is a key molecule against oxidative stress in Trypanosoma and Leishmania. It is not only unique to the parasite but is also crucial in maintaining the cellular redox potential and thus is essential for parasite survival. Trypanothione synthesis is catalyzed by two enzymes, namely, trypanothione synthetase (TS) (EC 6.3.1.9) and trypanothione reductase (TR) (EC 1.8.1.12). TS catalyzes trypanothione synthesis from two molecules of glutathione and spermidine (Fig. 7a) . Trypanothione is then maintained in its reduced form by the enzyme TR in the presence of NADPH (Fairlamb et al. 1985) . Reduced trypanothione in turn reduces tryparedoxin (TX) followed by reduction of tryparedoxin recycling enzyme tryparedoxin peroxidase (TP) (EC 1.11.1.15) (Fig. 7b) . Since, this is the only pathway that is crucially involved in regulating oxidative stress in these parasites; therefore, trypanothione pathway has become the focus of anti-trypanosomatid drug discovery. Both TR and TP have been shown to be important drug targets. Null mutants of TR show attenuated infectivity and decreased capacity to survive within intracellular macrophages (Dumas et al. 1997) . TR is similar in sequence and structure to its human counterpart, glutathione reductase. However, the active site of TR shows five non conservative changes in its active site, giving it overall negative charge which can accommodate trypanothione disulfide and gives the enzyme its specificity towards its substrate (Zhang et al. 1996) . This difference in substrate specificities has allowed synthesis of specific inhibitors against the parasite. Many lead compounds that inhibit TR have been identified including, polyamine derivatives, tricyclics and aminodiphenyl sulphides (Werbovetz 2000) . Trypanothione pathway thus, provides a promising drug target in trypanosomatids.
Topoisomerases as drug targets DNA topoisomerases are ubiquitous enzymes that play an important role in many essential processes like DNA replication, transcription, recombination and repair. They are broadly classified as type I and type II topoisomerases that cleave single stranded and double stranded DNA, respectively. DNA topoisomerases have been used as chemotherapeutic targets for anti-bacterial and anti-parasitic diseases. Type I topoisomerase (EC 5.99.1.2) have been characterized from L. donovani and T. cruzi. The enzyme was found to be independent of ATP (Das et al. 2004a) . L. donovani topoisomerase I was found to be present in both kinetoplast and nucleus (Das et al. 2004b ). Inhibitors of type I topoisomerase include anti-leishmanial compounds such as sodium stibogluconate and urea stibamine. Camptothecin, a plant alkaloid and a known inhibitor of eukaryotic topoisomerase I, was found to be inhibitory to T. brucei, T. cruzi and L. donovani. Analogs of camptothecin have also been screened against trypanosomes and the structural motifs have been identified which specifically inhibit the parasitic topoisomerase I with more potency (Bodley et al. 1995) . Topoisomerase II (EC 5.99.1.3) has been identified from T. brucei (Strauss and Wang 1990) , T. cruzi (Fragoso and Goldenberg 1992) and L. donovani (Das et al. 2001) . Interestingly, the topoisomerase II from T. brucei and L. donovani were found to contain both ATP dependent and independent activities. Topoisomerase II inhibitor, 9-anilinoacridine (used as anti-tumor agent) and other acridine derivatives inhibited Leishmania and Trypanosoma strongly (Figgitt et al. 1992 ). Dihydrobetulinic acid (DHBA), a derivative of betulinic acid (which is a pentacyclic triterpenoid) has been reported to be active against both Topoisomerase I and topoisomerase II from L. donovani (Chowdhury et al. 2003) . Three isoflavanoids, 8-prenylmucronulatol, lyasperin H and smiranicin have been found to be anti-leishmanial and this activity has been correlated to kDNA linearization and inhibition of topoisomerase II (Salem and Werbovetz 2005) . However, their use is limited due to their low cell toxicity. The structure of L. donovani topoisomerase I bound to nicked DNA captured as a vanadate complex has been elucidated (Davies et al. 2006) . The structural analysis of these enzymes will give us an insight into their catalytic mechanisms and will also enable us to design specific inhibitors against Leishmania.
Hypusine pathway
Hypusine (N e -(4-amino-2-hydroxybutyl) lysine), an unusual amino acid derived from the polyamine spermidine, is present in all the eukaryotes. Its name is derived from its two structural components, hydroxyputrescine and lysine (Shiba et al. 1971) . It is synthesized as a result of posttranslational modification occurring exclusively on one cellular protein, eukaryotic initiation factor 5A (eIF5A). It is formed in two enzymatic steps (Park et al. 1982) (Fig. 8) . The first step is catalyzed by the enzyme deoxyhypusine synthase (DHS) (EC 2.5.1.46) which catalyses the NAD ? dependent transfer of the 4-aminobutyl moiety of spermidine to a specific lysine residue of the eIF5A precursor protein to form an intermediate, deoxyhypusine (Chen and Dou 1988; Murphey and Gerner 1987) . This intermediate is subsequently hydroxylated by the enzyme deoxyhypusine hydroxylase (DOHH) (EC 1.14.99.29) (Abbruzzese et al. 1986 ) which completes the synthesis of hypusine and maturation of eIF5A.
Hypusination of eIF5A is necessary for its function and cell viability. Disruption of two eIF5A genes (TIF51A and TIF51B) (Schnier et al. 1991) and DHS gene (Park et al. 1998) from Saccharomyces cerevisiae produces a lethal phenotype. Inhibitors of hypusine biosynthetic enzymes, DHS (spermidine analogs) and DOHH (metal chelators) have been shown to exert anti-proliferative effects in mammalian cells including cancer cell lines (Park et al. 1994; Nishimura et al. 2005) . Recently, we have shown that hypusine biosynthesis occurs in Leishmania donovani. Interestingly, Leishmania has two genes containing DHS domains viz., DHS-like gene (DHSL20) and DHS34 gene, of which only DHS34 protein was found to contain functional activity in vitro. Null mutants of DHS34 gene could not be generated implying that the gene is essential to the parasite's survival (Chawla et al. 2010) . Structural modeling of DHS34 protein showed that one of the NAD ? binding domains lies in a 225-amino acid long insertion present in DHS34 protein as compared to the human homolog. The recombinant DHS34 remained uninhibited by most potent inhibitors of the human enzyme like GC 7 and other spermidine analogs, indicating that there is a difference between the spermidine binding sites of both the enzymes which could be exploited to design inhibitors.
Concluding remarks
Over the last decade, there has been a burst of activity towards the development of efficient drugs against the parasitic diseases including leishmaniasis. Target based drug discovery is being employed rather than the random screening of compounds, as the former approach produces more specific results. Many technological advances have been made, which has led to an extensive search for identification of novel drug targets. In the post-genomic era, a lot of proteins, enzymes, metabolites and pathways have been identified in trypanosomatids which are unique to these pathogens and could be exploited as drug targets. However, as outlined in the review, it is very critical to identify the suitable proteins or other metabolites to be used as drug targets. Several biochemical pathways have been discussed here which have been identified as targets for anti-leishmanial drug discovery. Glycolytic pathway, sterol biosynthesis and trypanothione pathway are quite distinct in Leishmania as compared to its mammalian host and therefore have been of interest for drug discovery. We have also identified a novel hypusine biosynthetic pathway in L. donovani. The enzyme DHS was found to be essential to the parasite and structurally different from the human homolog. The identified drug targets can then be used for high throughput screening with chemical libraries for which development of cheap and efficient assay system is required. Furthermore, refinement in the structure of the available compounds is required to synthesise more specific and effective inhibitors for these metabolic pathways. We have to combine all the technology and the information available with us to come up with more drug targets and eventually, with much needed new drugs to combat this deadly disease.
